Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Tomohisa Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7951-7429; OpenAlex author ID A5033152224. Sources: OpenAlex.

Their work

Papers
54 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
153
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 6 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: 5 papers · 2023: 10 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 54

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  2. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  3. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  4. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  5. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  6. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  7. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Co-author DOI 10.1016/j.pan.2024.03.012↗
  8. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  9. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  10. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  11. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  12. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  13. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  14. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  15. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. Co-author DOI 10.1080/01635581.2022.2107226↗
  16. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… First author DOI 10.21037/jgo-23-655↗
  17. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  18. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1026↗
  19. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  20. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  21. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  22. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  23. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Co-author DOI 10.1007/s00595-021-02308-3↗
  24. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  25. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  26. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC… Co-author DOI 10.3892/ol.2021.12786↗
  27. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12295↗
  28. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  29. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-01963-2↗
  30. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. First author DOI 10.1097/mpa.0000000000001579↗
  31. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061428↗
  32. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Co-author DOI 10.1016/j.pan.2019.03.001↗
  33. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  34. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  35. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospectiv… Co-author DOI 10.1002/jhbp.447↗
  36. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Co-author DOI 10.1007/s00595-016-1358-9↗
  37. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Co-author DOI 10.1097/sla.0000000000001705↗
  38. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  39. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal ade… Co-author DOI 10.1002/jhbp.408↗
  40. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  41. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarc… Co-author DOI 10.1080/01635581.2016.1134597↗
  42. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  43. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-016-0767-y↗
  44. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  45. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  46. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? Co-author DOI 10.1002/jhbp.119↗
  47. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000125↗
  48. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Co-author DOI 10.1007/s00534-012-0576-9↗
  49. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. Co-author DOI 10.1007/s11605-011-1795-0↗
  50. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. Co-author DOI 10.1016/j.jss.2010.09.027↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 47 shared papers, 2011–2025 · strength 4.41
  2. So Yamaki · 38 shared papers, 2011–2025 · strength 3.87
  3. Mitsugu Sekimoto · 17 shared papers, 2020–2024 · strength 2.50
  4. Daisuke Hashimoto · 16 shared papers, 2021–2025 · strength 2.34
  5. Satoshi Hirooka · 24 shared papers, 2011–2023 · strength 1.89
  6. Hiroaki Yanagimoto · 26 shared papers, 2011–2023 · strength 1.56
  7. Tsutomu Fujii · 11 shared papers, 2017–2025 · strength 1.29
  8. Tsukasa Ikeura · 7 shared papers, 2022–2023 · strength 1.10
  9. Tatsuma Sakaguchi · 6 shared papers, 2020–2023 · strength 0.85
  10. Hironori Ryota · 10 shared papers, 2016–2021 · strength 0.82
  11. Hiroki Yamaue · 8 shared papers, 2015–2025 · strength 0.80
  12. Michiaki Unno · 8 shared papers, 2015–2025 · strength 0.78
  13. Suguru Yamada · 6 shared papers, 2017–2024 · strength 0.72
  14. Satoshi Hirano · 6 shared papers, 2020–2025 · strength 0.69
  15. Fuyuhiko Motoi · 8 shared papers, 2015–2025 · strength 0.68
  16. Yasuhiro Kodera · 6 shared papers, 2017–2025 · strength 0.67
  17. Yuki Matsui · 4 shared papers, 2022–2023 · strength 0.66
  18. Masayuki Sho · 9 shared papers, 2015–2023 · strength 0.62
  19. Takahiro Akahori · 8 shared papers, 2015–2025 · strength 0.61
  20. Ippei Matsumoto · 6 shared papers, 2015–2025 · strength 0.60
  21. Joji Kitayama · 5 shared papers, 2020–2025 · strength 0.60
  22. Masanori Kon · 9 shared papers, 2016–2018 · strength 0.51
  23. Minako Nagai · 7 shared papers, 2015–2023 · strength 0.51
  24. Yosuke Inoue · 3 shared papers, 2023–2025 · strength 0.46
  25. Yoshiaki Murakami · 6 shared papers, 2015–2023 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.